Shares of Bio-Techne Corp. TECH rose 3.72% to $75.25 Wednesday, on what proved to be an all-around favorable trading session ...

Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks ...

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will ...

Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39.

The S&P 500 Index ($SPX) (SPY) today is down -0.20%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.04%, and the ...

The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.

Bio-Techne Corporation (TECH) stock climbs as its Q2 FY25 results exceed Wall Street estimates amid recovery in the biopharma end market. Read more here.

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, ...

Boston Scientific Corporation generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent ...

Bio-Techne Corp. (TECH) announced earnings for its second quarter that increased from last year and beat the Street estimates. The ...

OPEC oil output fell in January for a second month, a Reuters survey found, as a drop in exports from Nigeria and Iran offset ...

Bio-Techne beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop therapies ...